# | Filing Date | Period End Date | Type | Report Link |
---|---|---|---|---|
No Data found |
# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
Wedbush analyst Daniel Ives maintains Praxis Precision Medicine (NASDAQ:PRAX) with a Underperform and raises the price targe...
Truist Securities analyst Joon Lee reiterates Praxis Precision Medicine (NASDAQ:PRAX) with a Buy and raises the price target...
Guggenheim analyst Yatin Suneja maintains Praxis Precision Medicine (NASDAQ:PRAX) with a Buy and raises the price target fro...
Chardan Capital analyst Rudy Li maintains Praxis Precision Medicine (NASDAQ:PRAX) with a Buy and raises the price target fro...
Deutsche Bank analyst David Hoang maintains Praxis Precision Medicine (NASDAQ:PRAX) with a Buy and raises the price target f...
Praxis Precision Medicines, Inc. (NASDAQ:PRAX), a clinical-stage biopharmaceutical company translating genetic insights into th...